{"reformulated1": "How do cleavable versus non-cleavable linker chemistries affect the systemic toxicity and efficacy profiles of ADCs after intravenous administration?", "reformulated2": "What impact does the choice of conjugation site and DAR (drug-to-antibody ratio) have on the plasma stability and therapeutic window of antibody-drug conjugates?", "reformulated3": "Which innovative linker modifications, such as tandem-cleavage or steric hindrance, have shown the most promise in reducing off-target toxicity from ADCs while preserving on-target potency in preclinical models?"}
